ORBi: Detailled Reference

Article (Scientific journals)

Traitement de l'osteoporose post-menopausique: quoi de neuf en 2014?

Reginster, Jean-Yves; NEUPREZ, Audrey; LECART, Marie-Paule et al.

2014 • In Revue Médicale de Liège, 69 (7-8), p. 441-53

Peer reviewed

Permalink
https://hdl.handle.net/2268/172521

PubMed
25158386

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Traitement de l'ostéoporose post-ménopausique quoi de neuf en 2014.pdf

Publisher postprint (206.97 kB)

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Abstract :

[en] Management of osteoporosis involves both non pharmacological approaches, including changes in lifestyle and dietary habits combined, in patients at high risk of fracture or presenting with an established osteoporosis, to the use of drugs. Besides supplementation in calcium and vitamin D (at daily doses of 1 gr and 800 IU) in patients whose dietary intakes do not cover the recommended daily allowances, medications to be used for the management of osteoporosis may include inhibitors of bone resorption (bisphosphonates, denosumab and selective estrogen receptor modulators), stimulators of bone formation (teriparatide) or chemical entities decreasing bone resorption and stimulating bone formation (strontium ranelate). The selection of a particular medication, for a single individual patient, will depend on the severity of the disease as well as on the patient's believes and expectations. Local, skeletal and systemic tolerance of the various drugs should also be taken into account.

Disciplines :

General & internal medicine

Author, co-author :

Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé

NEUPREZ, Audrey ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé

LECART, Marie-Paule ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de gériatrie

Sarlet, Nathalie ; Centre Hospitalier Universitaire de Liège - CHU > Autres Services Médicaux > Service de médecine de l'appareil locomoteur

Distèche, Stéphan ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé

Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé

Language :

French

Title :

Traitement de l'osteoporose post-menopausique: quoi de neuf en 2014?

Alternative titles :

[en] Treatment of post-menopausic osteoporosis: what's new in 2014?

Publication date :

2014

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

69

Issue :

7-8

Pages :

441-53

Peer reviewed :

Peer reviewed

Available on ORBi :

since 03 October 2014

Statistics

Number of views

281 (17 by ULiège)

Number of downloads

786 (17 by ULiège)

More statistics

Scopus citations^®

3

Scopus citations^®
without self-citations

2

Bibliography

Kanis JA, McCloskey EV, Johansson H, et al. - European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int, 2013, 24, 23-57.
Kanis JA, Johnell O, Oden A, et al. - Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int, 2000, 11, 669-674.
Hernlund E, Svedbom A, Ivergard M, et al. - Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos, 2013, 8, 136.
Gehlbach S, Saag KG, Adachi JD, et al. - Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of osteoporosis in Women. J Bone Miner Res, 2012, 27, 645-653.
Body JJ, Bergmann P, Boonen S, et al. - Non-pharmacological management of osteoporosis : a consensus of the Belgian Bone Club. Osteoporos Int, 2011, 22, 2769-2688.
Body JJ, Bergmann P, Boonen S, et al. - Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis : a consensus document by the Belgian Bone Club. Osteoporos Int, 2010, 21, 1657-1680.
Rizzoli R, Bonjour JP, Ferrari SL. - Osteoporosis, genetics and hormones. J Mol Endocrinol, 2001, 26, 79-94.
Krall EA, Dawson-Hughes B. - Heritable and life-style determinants of bone mineral density. J Bone Miner Res, 1993, 8, 1-9. (Pubitemid 23033990)
Badurski JE, Kanis JA, Johansson H, et al. - The application of FRAX® to determine intervention thresholds in osteoporosis treatment in Poland. Pol Arch Med Wewn, 2011, 121, 148-155.
Bonjour JP, Guéguen L, Palacios C, et al. - Minerals and vitamins in bone health : the potential value of dietary enhancement. Br J Nutr, 20019, 10, 1581-1596.
Leslie WD, Majumdar SR, Lix LM, et al. - High fracture probability with FRAX usually indicates densitometric osteoporosis : implications for clinical practice. Osteoporos Int, 2012, 23, 391-397.
Rizzoli R, Boonen S, Brandi ML, et al. - Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr Med Res Opin, 2013, 29, 305-313.
Ström O, Borgström, F, Kanis JA, et al. - Osteoporosis : burden, health care provision and opportunities in the EU : a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch. Osteoporos, 2011, 6, 59-155.
Reginster JY. - Calcium and vitamin D for osteoporotic fracture risk. Lancet, 2007, 370, 632-634.
Tang BM, Eslick GD, Nowson C, et al. - Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older : a meta-analysis. Lancet, 2007, 370, 657-666. (Pubitemid 47285316)
Rizzoli R. - Nutrition : its role in bone health. Best Pract Res Clin Endocrinol Metab, 2008, 22, 813-829.
Body JJ, Bergmann P, Boonen S, et al. - Extraskeletal benefits and risks of calcium, vitamin D and antiosteoporosis medications. Osteoporos Int, 2012, 23, suppl. 1, S1-23.
Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, et al. - Fall prevention with supplemental and active forms of vitamin D : a meta-analysis of randomized controlled trials. BMJ, 2009, 339, b3692.
Smith H, Anderson F, Raphael H, et al. - Effect of annual intramuscular vitamin D on fracture risk in elderly men and women a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology, 2007, 46, 1852-1857. (Pubitemid 350168304)
Sanders KM, Stuart AL, Williamson EJ, et al. - Annual high-dose oral vitamin D and falls and fractures in older women : a randomized controlled trial. JAMA, 2010, 303, 1815-1822.
Liu-Ambrose T, Eng JJ, Khan KM, et al. - Older women with osteoporosis have increased postural sway and weaker quadriceps strength than counterparts with normal bone mass : overlooked determinants of fracture risk. J Gerontol A Biol Sci Med Sci, 2003, 58, M862-866.
Khan SA, Kanis JA, Vasikaran S, et al. - Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res, 1997, 12, 1700-1707. (Pubitemid 27422371)
Black DM, Cummings SR, Karpf DB, et al. - Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet, 1996, 7, 1535-1541. (Pubitemid 26411651)
Cummings SR, Black DM, Thompson DE, et al. - Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA, 1998, 280, 2077-2082. (Pubitemid 29014065)
De Groen PC, Lubbe DF, Hirsch L, et al. - Esophagitis associated with the use of alendronate. N Engl J Med, 1996, 335, 1016-1021.
Harris ST, Watts N, Genant HK, et al. - Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) study group. JAMA, 1999, 282, 1344-1352. (Pubitemid 29483192)
Reginster JY, Minne HW, Sorensen OH, et al. - Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) study group. Osteoporos Int, 2000, 11, 83-91. (Pubitemid 30099515)
McClung MR, Geusens P, Miller PD, et al. - Effect of risedronate on the risk of hip fracture in elderly women. Hip intervention program study group. N Engl J Med, 2001, 344, 333-340. (Pubitemid 32107641)
Chesnut III CH, Skag A, Christiaensen C, et al. - Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res, 2004, 19, 1241-1249. (Pubitemid 41094364)
Delmas PD, Recker RR, Chesnut CH 3rd, etal. - Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk : results from the BONE study. Osteoporos Int, 2004, 15, 792-798. (Pubitemid 39361949)
Reginster JY, Adami S, Lakatos P, et al. - Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis : 2 year results from the MOBILE study. Ann Rheum Dis, 2006, 65, 654-661.
Eisman JA, Civitelli R, Adami S, et al. - Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis : 2-year results from the DIVA study. J Rheumatol, 2008, 35, 488-497. (Pubitemid 351374427)
Harris ST, Reginster JY, Harley C, et al. - Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. Bone, 2009, 44, 758-765.
Black DM, Delmas PD, Eastell R, et al. - Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med, 2007, 356, 1809-1822. (Pubitemid 46698462)
Lyles KW, Colon-Emeric CS, Magaziner JS, et al. - Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med, 2007, 357, nihpa40967.
Rizzoli R, Reginster JY, Boonen S, et al. - Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif. Tissue Int, 2011, 89, 91-104.
Weycker D, Macarios D, Edelsberg J, et al. - Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int, 2007, 18, 271-277. (Pubitemid 46233172)
Rabenda V, Vanoverloop J, Fabri V, et al. - Low incidence of anti-osteoporosis treatment after hip fracture. J Bone Joint Surg Am, 2008, 90, 2142-2148.
Rabenda V, Mertens R, Fabri V, et al. - Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int, 2008, 19, 811-818.
Tadrous M, Wong L, Mamdani MM, et al. - Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis : a network meta-analysis. Osteoporos Int, 2014, 25, 1225-1235.
Hiligsmann M, Rabenda V, Bruyère O, et al. - The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy, 2010, 96, 170-177.
Powles TJ, Hickish T, Kanis JA, et al. - Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol, 1996, 14, 78-84. (Pubitemid 26022463)
Ettinger B, Black DM, Mitlak BH, et al. - Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA, 1999, 18, 637-645. (Pubitemid 29384151)
Delmas PD, Genant HK, Crans GG, et al. - Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures : results from the MORE trial. Bone, 2003, 33, 522-532. (Pubitemid 37222378)
Vogel VG, Costantino JP, Wickerham DL, et al. - Effects of tamoxifen vs raloxigene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA, 2006, 295, 2727-2741.
Lecart MP, Reginster JY. - Current options for the management of postmenopausal osteoporosis. Expert Opin Pharmacother, 2011, 12, 2533-2552.
Cummings SR, San martin J, McClung MR, et al. - Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med, 2009, 361, 456-465.
Bone HG, Chapurlat R, Brandi ML, et al. - The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab, 2013, 98, 4483-4492.
Bone HG, Bolognese MA, Yuen CK, et al. - Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab, 2011, 96, 972-980.
Neer RM, Arnaud CD, Zanchetta JR, et al. - Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med, 2001, 344, 1434-1441. (Pubitemid 32402100)
Prince R, Sipos A, Hossain A, et al. - Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res, 2005, 20, 1507-1513. (Pubitemid 41243539)
Lecart MP, Bruyère O, Reginster JY. - Combination/sequential therapy in osteoporosis. Curr Osteoporos Rep, 2004, 2, 123-130.
Reginster JY, Deroisy R, Jupsin J. - Strontium ranelate: a new paradigm in the treatment of osteoporosis. Drugs Today (Barc), 2003, 39, 89-101. (Pubitemid 36514361)
Meunier PJ, Roux C, Seeman E, et al. - The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med, 2004, 29, 459-468. (Pubitemid 38133766)
Reginster JY, Seeman E, De Vernejoul MC, et al. - Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab, 2005, 90, 2816-2822. (Pubitemid 40686329)
Reginster JY, Kaufman JM, Goemaere S, et al. - Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporos Int, 2012, 23, 1115-1122.
Rizzoli R, Reginster JY. - Adverse drug reactions to osteoporosis treatments. Expert Rev Clin Pharmacol, 2011, 4, 593-604.
Musette P, Kaufman JM, Rizzoli R, et al. - Cutaneous side effects of antiosteoporosis treatments. Ther Adv Musculoskelet Dis, 2011, 3, 31-41.
Bostick RM, Kuschi LH, Wu Y, et al. - Relation of calcium, vitamin D, and dairy food iintake to ischemic heart disease mortality among postmenopausal women. Am J Epidemiol, 1999, 149, 151-161. (Pubitemid 29039518)
Al-Delaimy WK, Rimm E, Willett WC, et al. - A prospective study of calcium intake from diet and supplements and risk of ischemic heart disease among men. Am J Clin Nutr, 2003, 77, 814-8
Bockman RS, Zapalowski C, Kiel DP, et al. - Commentary on calcium supplements and cardiovascular events. J Clin Densitom, 2012, 15, 130-134.
Bolland MJ, Barber PA, Doughty RN, et al. - Vascular events in healthy older women receiving calcium supplementation : randomized controlled trial. BMJ, 2008, 236, 262-236.
Bolland MJ, Avenell A, Baron JA, et al. - Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ, 2010, 341, c3691.
Bolland MJ, Grey A, Avenell A, et al. - Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ, 2011, 19, 342, d2040.
Prentice RL, Pettinger MB, Jackson RD, et al. - Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study. Osteoporos Int, 2013, 24, 567-580.
Cauley JA, Chlebowski RT, Wactawski-Wende J, et al. - Calcium plus vitamin D supplementation and health outcomes five years after active intervention ended : the Women's Health Initiative. J Womens Health (Larchmt), 2013, 22, 915-929.
Pentti K, Tuppurainen MT, Honkanen R, et al. - Use of calcium supplements and the risk of coronary heart disease in 52-62-year-old women : the kuopio osteoporosis risk factor and prevention study. Maturitas, 2009, 63, 73-78.
Li K, Kaaks R, Linseisen J, et al. - Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European Prospective Investigation into cancer and Nutrition study (EPIC-Heidelberg). Heart, 2012, 98, 920-925.
Lewis JR, Calver J, Zhu K, et al. - Calcium supplementation and the risks of atherosclerotic vascular disease in older women : results of a 5-year RCT and 4.5-year follow-up. J Bone Miner Res, 2011, 26, 35-41.
Wang L, Manson JE, Song Y, et al. - Systematic review : vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med, 2010, 152, 315-323.
Wang L, Manson JE, Sesso HD. - Calcium intake and risk of cardiovascular disease : a review of prospective studies and randomized clinical trials. Am J Cardiovasc Drugs, 2012, 12, 105-116.
Bruyère O, De Cock C, Mottet C, et al. - Low dietary calcium in European postmenopausal osteoporotic women. Public Health Nutr, 2009, 12, 111-114.
Donneau AF, Reginster JY. - Cardiovascular safety of strontium ranelate : real-life assessment in clinical practice. Osteoporos Int, 2014, 25, 397-398.
Cooper C, Fox KM, Borer JS. - Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis : a nested case-control study in the CPRD. Osteoporos Int, 2014, 25, 737-746.
Abrahamsen B, Grove EL, Vestergaard P. - Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate. Osteoporos Int, 2014, 25, 757-762.
Devogelaer JP, Reginster JY, Rompen E, et al. - L'ostéoné crose maxillaire associée aux traitements aux bisphosphonates dans le traitement de l'ostéoporose. Consensus interdisciplinaire. Louvain Med, 2010, 129, 305-309.
Rizzoli R, Burlet N, Cahall D, et al. - Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone, 2008, 42, 841-847.
Bamais A, Kastritis E, Bamia C, et al. - Osteonecrosis of the jaw in cancer after treatment with bisphosphonates : incidence and risk factors. J Clin Oncol, 2005, 23, 8580-8587. (Pubitemid 46211499)
Sanna G, Preda L, Bruschini R, et al. - Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer. Ann Oncol, 2006, 17, 1512-1516. (Pubitemid 44542036)
Solomon DH, Mercer E, Woo SB, et al. - Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw : prior work and current challenges. Osteoporos Int, 2013, 24, 237-244.
Sedghizadeh PP, Staley K, Caligiuri M, et al. - Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc, 2009, 140, 61-66.
Stopeck AT, Lipton A, Body JJ, et al. - Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer : a randomized, double-blind study. J Clin Oncol, 2010, 28, 5132-5139.
Diab DL, Watts NG. - Denosumab in osteoporosis. Expert Opin Dug Saf, 2014, 13, 247-253.
Neuprez A, Coste S, Rompen E, Crielaard JM, Reginster JY - Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab. Osteoporos Int, 2014, 25, 393-395.
Marx RE, Cillo JE Jr, Ulloa JJ. - Oral bisphosphonate-induced osteonecrosis : risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg, 2007, 65, 2397-2410. (Pubitemid 350100982)
Shane E, Burr D, Ebeling PR, et al. - Atypical subtrochonteric and diaphyseal femoral fractures : a report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res, 2010, 25, 2267-2294.
Shane E, Burr D, Abrahamsen B, et al. - Atypical subtrochanteric and diaphyseal femoral fractures : second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res, 2014, 29, 1-23.
Black DM, Schwartz AV, Ensrud KE, et al. - Effects of continuing or stopping alendronate after 5 years of treatment: the Facture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA, 2006, 296, 2927-2938. (Pubitemid 46021497)
Grey A, Bolland M, Mihov B, et al. - Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women : a randomized, placebo-controlled trial. J Bone Miner Res, 2014, 29, 166-172.

Similar publications